Tag:
Menveo
Latest Headlines
Latest Headlines
Novartis meningitis vax faces tough fight
Novartis ( $NVS ) saw a setback on its meningitis vaccine Menveo earlier this month, when the FDA unexpectedly rejected a version designed for use in infants.
FDA says no to Novartis' Menveo vax for babies
Novartis ( $NVS ) has suffered a setback in its effort to expand the use of Menveo , its quadrivalent meningococcal conjugate vaccine. The FDA has turned down its application to extend the approval to
Novartis dealt another setback to broader Menveo use
Novartis ( $NVS ) hit another snag in its quest to broaden use of the meningococcal vaccine Menveo. The FDA has asked for more information on Menveo use in infants, delaying the company's ability to
CDC panel backs additional vax doses
Good news for makers of the meningitis vaccine--sort of. A CDC advisory panel recommended a booster shot for teenagers, effectively doubling the number of shots kids would get--and doubling the
Vax panel votes to add meningitis booster dose
The CDC's Advisory Committee on Immunization Practices voted 6-5 Wednesday to add a booster dose of the meningitis vaccine at age 16. Reuters notes that health officials want to address waning
Study boosts Novartis vax's bid for infant OK
What's the best way to boost sales of a key vaccine? Get it approved for infants, of course. And Novartis is one step closer to doing just that with Menveo, its meningococcal shot. Now approved for
Group wants investigation into Sanofi, Merck contracts
The nonprofit group Citizens for Responsibility and Ethics in Washington has sent a letter to the FTC requesting an antitrust investigation into drugmakers that it alleges have offered significant
EC approves Novartis' Menveo conjugate vax
Just a few weeks after gaining an approval from the FDA , Novartis says that officials from the European Commission have provided a continental OK for its meningitis vaccine blockbuster Menveo. Menveo
Novartis gets Menveo vaccine approval
The FDA has approved Novartis' Menveo vaccine for use in 11-55 year olds to help protect against meningitis and sepsis caused by four common vaccine-preventable serogroups. That approval could help
Novartis delayed on Menveo app
The FDA has asked Novartis for more information on its meningitis vaccine Menveo, which is likely to push back any approval date to late this year or early in 2010. And the manufacturer was quick to
